| DB ID | MyCo_1096 |
| Title | A comprehensive diagnostic approach using galactomannan, targeted β-d-glucan, baseline computerized tomography and biopsy yields a significant burden of invasive fungal disease in at risk haematology patients |
| Year | 2014 |
| PMID | 25179933 |
| Fungal Diseases involved | Invasive fungal infection |
| Associated Medical Condition | Haematology patients |
| Genus | Candida |
| Species | glabrata |
| Organism | Candida glabrata |
| Ethical Statement | The study was approved by the local ethics committee and conducted in accordance with the Hel- sinki protocol (2008 revision) for medical research involving human subjects and registered with the ClinicalTrials.gov (NCT00816088). |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | UK |
| Cohort | A total of 203 consecutive patients were prospectively recruited from King’s College Hospital from December 2008 to May 2010. |
| Cohort No. | 203 |
| Age Group | 19–73 |
| P Value | None |
| Sensitivity | 0.833 |
| Specificity | 0.984 |
| Positive Predictive Value | 0.901 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Assay |
| Analysis Method | BDG assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | BDG Assay,GM Assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
